Business
Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium
WESTPORT, Conn., Dec. 1, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and
About this update from Intensity Therapeutics, Inc.
[{"type":"text","content":"WESTPORT, Conn., Dec. 1, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that it has been selected for a spotlight oral presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS) on December 8, 2023. Dr. Angel Arnaout will be conducting the oral presentation which will highlight the efficacy and immunomodulatory effects of INT230-6 in early-stage breast cancer.\n\n \n \n \n \n \n \n\n \nSpotlight Oral Presentation Details\nConcurrent Poster Spotlight Session Block #6PS16 Enhancing Immunotherapy for Triple Negative Breast Cancer: Novel Therapies and BiomarkersModerator: Hope S. Rugo, MD, FASCO, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CaliforniaTitle: Intra-tumoral dosing of INT230-6 in early-stage breast cancer patients induces tumor cell necrosis and immunomodulatory effects: A phase II randomized window-of-opportunity study – the INVINCIBLE trialPresentation #: PS16-03Date and Time: Friday, December 8, 7:00 – 8:00 a.m. CTLocation: Stars at Night Ballroom 3 & 4Presenter: Angel Arnaout, M.D., MSc, Ottawa Hospital Research Institute, Ontario Institute of Cancer ResearchDiscussant: Sangeetha Reddy, M.D., M.S.C.I., UT Southwestern Medical Center, Dallas, Texas\nAbout Intensity TherapeuticsIntensity Therapeutics, Inc. is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. Intensity leverages its DfuseRx℠ technology platform to create proprietary drug formulations that following direct injection rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive immune response that not only attacks the injected tumor, but also non-injected tumors. The Company's lead product candidate, INT230-6, is in development for the treatment of patients with solid tumors, such as sarcoma and breast cancer. Intensity has a clinical collaboration agreement with Merck Sharpe & Dohme (Merck) to evaluate INT230-6 with pembrolizumab. In addition, the Company has a clinical collaboration ...